|
1
|
Cordo V, van der Zwet JCG, Cante-Barrett
K, Pieters R and Meijerink JPP: T-cell acute lymphoblastic
leukemia: A roadmap to targeted therapies. Blood Cancer Discov.
2:19–31. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hughes AD, Polonen P and Teachey DT:
Relapsed childhood T-cell acute lymphoblastic leukemia and
lymphoblastic lymphoma. Haematologica. 110:1934–1950.
2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Marks DI and Rowntree C: Management of
adults with T-cell lymphoblastic leukemia. Blood. 129:1134–1142.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shams S and Patel CB: Anti-cancer
mechanisms of action of therapeutic alternating electric fields
(tumor treating fields [TTFields]). J Mol Cell Biol.
14(mjac047)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stupp R, Taillibert S, Kanner A, Read W,
Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K,
Di Meco F, et al: Effect of tumor-treating fields plus maintenance
temozolomide vs maintenance temozolomide alone on survival in
patients with glioblastoma: A randomized clinical trial. JAMA.
318:2306–2316. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Leal T, Kotecha R, Ramlau R, Zhang L,
Milanowski J, Cobo M, Roubec J, Petruzelka L, Havel L, Kalmadi S,
Ward J, et al: Tumor treating fields therapy with standard systemic
therapy versus standard systemic therapy alone in metastatic
non-small-cell lung cancer following progression on or after
platinum-based therapy (LUNAR): A randomised, open-label, pivotal
phase 3 study. Lancet Oncol. 24:1002–1017. 2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Babiker HM, Picozzi V, Chandana SR,
Melichar B, Kasi A, Gang J, Gallego J, Bullock A, Chunyi H, Wyrwicz
L, Hitre E, et al: Tumor treating fields with gemcitabine and
nab-paclitaxel for locally advanced pancreatic adenocarcinoma:
Randomized, open-label, pivotal phase III PANOVA-3 study. J Clin
Oncol. 43:2350–2360. 2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Homami E, Goliaei B, Shariatpanahi SP and
Habibi-Kelishomi Z: Alternating electric fields can improve
chemotherapy treatment efficacy in blood cancer cell U937
(non-adherent cells). BMC Cancer. 23(861)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Abadijoo H, Khayamian MA, Faramarzpour M,
Ghaderinia M, Simaee H, Shalileh S, Yazdanparast SM, Ghabraie B,
Makarem J, Sarrami-Forooshani R and Abdolahad M: Healing field:
using alternating electric fields to prevent cytokine storm by
suppressing clonal expansion of the activated lymphocytes in the
blood sample of the COVID-19 patients. Front Bioeng Biotechnol.
10(850571)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nasori N, Firdhaus M, Farahdina U and
Khamimatul Ula R: Optimizing tumor treating fields for blood cancer
therapy: Analysis of electric field distribution and dose density.
Biophys Physicobiol. 21(e210013)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Follini E, Marchesini M and Roti G:
Strategies to overcome resistance mechanisms in T-cell acute
lymphoblastic leukemia. Int J Mol Sci. 20(3021)2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nishikawa R, Yamasaki F, Arakawa Y,
Muragaki Y, Narita Y, Tanaka S, Yamaguchi S, Mukasa A and Kanamori
M: Safety and efficacy of tumor treating fields (TTFields) therapy
for newly diagnosed glioblastoma in Japanese patients using the
NovoTTF system: A prospective post-approval study. Jpn J Clin
Oncol. 53:371–377. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ceresoli GL and Gianoncelli L: Tumor
treating fields (TTFields) therapy in unresectable pleural
mesothelioma: Overview of efficacy, safety, and future outlook.
Curr Treat Options Oncol. 26:398–414. 2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Serventi JN and Newton HB: Tumor treating
fields: An innovative therapy for glioblastoma and other solid
tumors. J Adv Pract Oncol. 16:181–191. 2025.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li X, Liu K, Xing L and Rubinsky B: A
review of tumor treating fields (TTFields): Advancements in
clinical applications and mechanistic insights. Radiol Oncol.
57:279–291. 2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yue Y, Wang Y, Feng J, Yao M and Suo Y:
Tumor treating fields suppress tumor cell growth and induce
immunogenic cell death biomarkers in biliary tract cancer cell
lines. Sci Rep. 15(30611)2025.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cai Z, Yang Z, Wang Y, Li Y, Zhao H, Zhao
H, Yang X, Wang C, Meng T, Tong X, et al: Tumor treating induced
fields: A new treatment option for patients with glioblastoma.
Front Neurol. 15(1413236)2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mao H, Zhao X and Sun SC: NF-κB in
inflammation and cancer. Cell Mol Immunol. 22:811–839.
2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Eggert J, Zinzow-Kramer WM, Hu Y, Kolawole
EM, Tsai YL, Weiss A, Evavold BD, Salaita K, Scharer CD and
Au-Yeung BB: CBL-B mitigates the responsiveness of naïve CD8(+) T
cells that experience extensive tonic T cell receptor signaling.
Sci Signal. 17(eadh0439)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Laletin V, Bernard PL, Costa da Silva C,
Guittard G and Nunes JA: Negative intracellular regulators of
T-cell receptor (TCR) signaling as potential antitumor
immunotherapy targets. J Immunother Cancer.
11(e005845)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wu T, Tan JHL, Sin WX, Luah YH, Tan SY,
Goh M, Birnbaum ME, Chen Q and Cheow LF: Cell granularity reflects
immune cell function and enables selection of lymphocytes with
superior attributes for immunotherapy. Adv Sci (Weinh).
10(e2302175)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xiao B, Deng X, Zhou W and Tan EK: Flow
cytometry-based assessment of mitophagy using MitoTracker. Front
Cell Neurosci. 10(76)2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Doherty E and Perl A: Measurement of
mitochondrial mass by flow cytometry during oxidative stress. React
Oxyg Species (Apex). 4:275–283. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Guo C, Sun L, Chen X and Zhang D:
Oxidative stress, mitochondrial damage and neurodegenerative
diseases. Neural Regen Res. 8:2003–2014. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
González-García S, García-Peydró M,
Martín-Gayo E, Ballestar E, Esteller M, Bornstein R, et al: NRARP
displays either pro- or anti-tumoral roles in T-cell acute
lymphoblastic leukemia. Cell Death Dis. 10(671)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Alabed M, Cardenas C, Kipp JL, O'Connor D,
Breitkopf SB, Carrasco DR, et al: Metabolic heterogeneity defines
distinct vulnerabilities in T-cell acute lymphoblastic leukemia.
Int J Mol Sci. 25(3921)2024.
|
